{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,4,22]],"date-time":"2026-04-22T09:34:30Z","timestamp":1776850470206,"version":"3.51.2"},"reference-count":0,"publisher":"S. Karger AG","license":[{"start":{"date-parts":[[2017,8,11]],"date-time":"2017-08-11T00:00:00Z","timestamp":1502409600000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/karger.com\/pages\/terms-and-conditions"},{"start":{"date-parts":[[2017,8,11]],"date-time":"2017-08-11T00:00:00Z","timestamp":1502409600000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/karger.com\/pages\/terms-and-conditions"}],"content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":["Dev Pharmacol Ther"],"abstract":"<jats:p>Anisodamine, an anticholinergic drug, is widely used in China\nfor treatment of infants with septic shock and has been reported\nto inhibit thromboxane synthesis in cultured cells. Thromboxane\nA(2) plays an important role in the early pulmonary hypertension\nin sepsis; however, the role of thromboxane A(2) later in\nsepsis is unclear. We tested the hypotheses that thromboxane\nA(2) synthesis inhibition with dazmegrel, and cholinergic blockade\nwith anisodamine, would attenuate the later phase of pulmonary\nhypertension induced by 4 h of group B streptococcus\n(GBS) infusion. 1 mg\/kg of dazmegrel reversed the pulmonary\nhypertension and slightly increased cardiac output; these hemodynamic\nimprovements persisted for 30-60 min. Plasma\nthromboxane B(2) levels returned toward pre-GBS baseline values\nafter dazmegrel treatment. Thus, thromboxane A(2) is still a\nmajor mediator of pulmonary hypertension in piglets after 4 h\nof continuous GBS infusion. 0.5 mg\/kg of anisodamine had no\nsignificant hemodynamic effect. 2 and 4 mg\/kg of anisodamine\neach caused transient, dose-related decreases in systemic artery\npressure; cardiac output also fell after the highest anisodamine\ndose. Pulmonary hypertension was not alleviated by anisodamine.\nAll hemodynamic changes induced by anisodamine were\nshort-lived and returned to preanisodamine values within 10\nmin. Anisodamine did not ameliorate thromboxane-mediated\npulmonary hypertension in this animal model, and therefore\nmay not inhibit thromboxane synthesis in vivo. The results of\nthis study do not support the use of anticholinergic therapy to\nimprove hemodynamics in GBS sepsis, but do suggest that\nthromboxane synthesis inhibition may be a clinically useful\ntherapy in advanced GBS sepsis.<\/jats:p>","DOI":"10.1159\/000457461","type":"journal-article","created":{"date-parts":[[2017,8,11]],"date-time":"2017-08-11T17:08:18Z","timestamp":1502471298000},"page":"40-49","source":"Crossref","is-referenced-by-count":3,"title":["Delayed Thromboxane Synthesis Inhibition, But Not Cholinergic Blockade, Reverses Group B Streptococcus-Induced Pulmonary Hypertension"],"prefix":"10.1159","author":[{"given":"Jia-Xian","family":"Li","sequence":"first","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Barry M.","family":"Gray","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"James R.","family":"Oliver","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Chong-Yuan","family":"Lu","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Joseph B.","family":"Philips, III","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"127","published-online":{"date-parts":[[2017,8,11]]},"container-title":["Developmental Pharmacology and Therapeutics"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/karger.com\/article-pdf\/doi\/10.1159\/000457461","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2026,4,22]],"date-time":"2026-04-22T08:34:20Z","timestamp":1776846860000},"score":1,"resource":{"primary":{"URL":"https:\/\/karger.com\/article\/doi\/10.1159\/000457461"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2017,8,11]]},"references-count":0,"URL":"https:\/\/doi.org\/10.1159\/000457461","archive":["Portico"],"relation":{},"ISSN":["0379-8305","2504-2505"],"issn-type":[{"value":"0379-8305","type":"print"},{"value":"2504-2505","type":"electronic"}],"subject":[],"published":{"date-parts":[[2017,8,11]]}}}